LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma
J. Tabernero(Vall d'Hebron Hospital Universitari), S-E. Al-Batran(University Hospital Frankfurt), Zev A. Wainberg(University of California, Los Angeles), K. Muro(Aichi Cancer Center), D. Molena(Cornell University), E. Van Cutsem(KU Leuven), Woo Jin Hyung(Yonsei University), L.S. Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), D-Y. Oh(Seoul National University Hospital), Takeshi Omori(Osaka International Cancer Institute), M. Moehler, Arinilda Campos Bragagnoli(Hospital de Câncer de Barretos), Gabriel Garbaos(Fundación Centro de Estudios Infectológicos), M. Liberman(Centre Hospitalier de l’Université de Montréal), María Luisa Limón(Hospital Universitario Virgen del Rocío), E.C. Smyth(Churchill Hospital), L-Y. Cheng(AstraZeneca (Netherlands)), Nicola Valeri(AstraZeneca (United Kingdom)), Ioannis Xynos(AstraZeneca (United Kingdom)), Y. Y. Janjigian(Cornell University)
Cited by 8
Abstract
Related Papers
No related papers found
Powered by citation graph analysis